Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20600826 | 0.78 | HDAC1 (0.34) | HDAC1HDAC6 | |
| SCHEMBL30525820 | 0.78 | HDAC1 (0.34) | HDAC1HDAC6 | |
| SCHEMBL1638888 | 0.76 | CES2 (0.38) | RAPGEF4PARP1 | |
| SCHEMBL2507662 | 0.76 | RAPGEF4 (0.39) | ALDH1A1RAPGEF4HDAC1HDAC6 | |
| SCHEMBL5511083 | 0.74 | RAPGEF4 (0.42) | RAPGEF4PARP1 | |
| SCHEMBL5512601 | 0.74 | HDAC1 (0.33) | HDAC1HDAC6 | |
| SCHEMBL113484 | 0.74 | ALDH1A1 (0.48) | ALDH1A1RAPGEF4HDAC1HDAC6 | |
| SCHEMBL21639542 | 0.74 | ERN1 (0.40) | ALDH1A1IKBKB | |
| SCHEMBL20051254 | 0.74 | CA1 (0.45) | ALDH1A1HDAC1HDAC6 | |
| SCHEMBL30961678 | 0.74 | CA1 (0.45) | ALDH1A1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125366-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260035335-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-4522583-A2 | PI3K ALPHA INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119486992-A | PI3K alpha inhibitors and methods of use thereof | 传达治疗有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240150287-A1 | N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | HANGZHOU APELOA MEDICINE RESEARCH INSTITUTE CO., LTD. (CN) | 2024-05-09 | — | — | US | disclosed |
| EP-4282865-A1 | N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Hangzhou Apeloa Medicine Research Institute Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| EP-4282865-A1 | N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Hangzhou Apeloa Medicine Research Institute Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023220131-A2 | PI3Kα INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220131-A2 | PI3Kα INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| CN-114853659-A | N- (benzoyl) -phenylalanine compounds, pharmaceutical compositions containing same, and uses thereof | 普洛药业股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| US-8883826-B2 | Alkynyl derivatives as modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2014-11-11 | — | — | US | disclosed |
| US-8674106-B2 | Alkynyl derivatives as modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20130178631-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2013-07-11 | — | — | US | disclosed |
| US-20120277237-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2012-11-01 | — | — | US | disclosed |
| EP-2426115-A2 | Alkynyl derivatives as modulators of metabotropic glutamate receptors | Addex Pharma SA (CH) | 2012-03-07 | — | — | EP | disclosed |
| US-8101637-B2 | Alkynyl derivatives as modulators of metatropic glutamate receptors | ADDEX PHARMA SA (CH) | 2012-01-24 | — | — | US | disclosed |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2009-05-14 | — | — | US | disclosed |
| EP-1765795-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharmaceuticals SA (CH) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123703-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CA, PIK3CB, PIK3CD | ALDH1A1 3698/4885RAPGEF4 361/4885HDAC1 828/4885 |
| US-20130178631-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | ALDH1A1 2153/4885RAPGEF4 1720/4885HDAC1 1728/4885 |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | ALDH1A1 2496/4885RAPGEF4 1646/4885HDAC1 1509/4885 |
| US-20240150287-A1 | N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | ITGB7, ITGB4, ITGA4 | ALDH1A1 988/4885RAPGEF4 1462/4885HDAC1 1311/4885 |
| US-20120277237-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | ALDH1A1 2153/4885RAPGEF4 1720/4885HDAC1 1728/4885 |
| US-20260125366-A1 | METHODS FOR TREATING CANCER | AKT2, AKT3, PIK3R5 | ALDH1A1 2246/4885RAPGEF4 2244/4885HDAC1 2176/4885 |
| US-20260035335-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CD, PIK3CG, PIK3CB | ALDH1A1 4597/4885RAPGEF4 395/4885HDAC1 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.